APMD

Healthcare Biotechnology

Apnimed, Inc.

$21.70

-0.23 -1.03% today Live

Price History

Not enough data

Price chart data
Date	Price
Oct 5, 2026, live at 1:40 PM ET	21.70

Key Stats

Market Cap

903.60M

Avg Volume

562,946

P/E (TTM)

3.01

EPS

$7.22

52W High

$35.29

52W Low

$16.12

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-5.46

P/B Ratio

-0.59

P/S Ratio

7.85

EV/EBITDA

29.22

EV/Revenue

9.11

Margins

Gross Margin 93.9%

Operating Margin (96.9%)

Net Margin 142.1%

EBITDA Margin 31.2%

Growth & Returns

Revenue Growth (YoY)

(29.4%)

Liquidity & Leverage

Current Ratio

5.19

Quick Ratio

4.88

Debt / Equity

1.15

Total Cash

172.80M

Total Debt

80.35M

About

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

apnimed.com